HOLLISTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Benchmark Healthcare House Call Virtual Conference on May 22nd, 2024, with a live fireside chat scheduled for 9:00-9:40 am ET. The Company will also be hosting one-on-one meetings with investors in conjunction with the Conference.
To register for the presentation, or to schedule a one-on-one meeting, please visit the Benchmark website at 2024 Benchmark Healthcare House Call Virtual Conference.
About Harvard Bioscience, Inc.
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world. For more information, please visit our website at www.harvardbioscience.com
Company Contact:
Harvard Bioscience
Jennifer Cote, Chief Financial Officer
(508) 893-3120
Investor Contacts:
Three Part Advisors
Sandy Martin / Erol Girgin / William Shelmire
This email address is being protected from spambots. You need JavaScript enabled to view it.
(214) 616-2207
| Last Trade: | US$0.33 |
| Daily Change: | -0.0042 -1.27 |
| Daily Volume: | 169,692 |
| Market Cap: | US$14.220M |
February 24, 2025 November 07, 2024 October 03, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
